FDA Panel Backs Approval Of Takeda/Orexigen's Obesity Drug Contrave
This article was originally published in PharmAsia News
Executive Summary
The promise of a randomized clinical trial to examine the cardiovascular risks of Orexigen's weight-loss drug Contrave - inlicensed by Takeda for North American commercialization and development rights - prompted a 13-7 vote in favor of approval by the agency's Endocrinologic and Metabolic Drugs Advisory Committee Dec. 7
You may also be interested in...
FDA, Orexigen Discussing CV Risk Study For Weight-Loss Drug Contrave
Timing of the study to be discussed at Dec. 7 advisory committee meeting.
Takeda Bulks Up In Obesity With Orexigen Deal
Takeda, already a strong player in diabetes, is looking to be a leader in obesity as well. Obesity is a risky area of drug development, given regulatory concerns about safety and efficacy, not to mention payer resistance. But despite those roadblocks, Takeda added to its substantial obesity pipeline through a deal with Orexigen Therapeutics, announced Sept. 2
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).